Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHTCF.L Regulatory News (HTCF)

  • There is currently no data for HTCF

Monthly Performance Review

21 Apr 2015 07:00

RNS Number : 7563K
BlueCrest AllBlue Fund Ltd
21 April 2015
 



FOR IMMEDIATE RELEASE

 

21 April 2015

 

BLUECREST ALLBLUE FUND LIMITED

MONTHLY PERFORMANCE REVIEW FOR MARCH 2015

 

"Strong returns despite quieter markets"

 

BlueCrest AllBlue Fund Limited (BCAB) rose by a further 1.0% in March which brings the year to date return to 2.6% (Sterling Class NAV). The rolling 12 month return was 7.7%. Once again, volatility remains low and stable at 1.8%.

 

The month's strong returns came despite quieter market conditions. Economic data surprised somewhat to the upside in Europe in contrast to the weaker, weather impacted data from the US. However, inflation everywhere was soft. Markets focused mostly on the continued activity of central banks, as the ECB implemented QE, rate cuts continued worldwide and the US FOMC omitted the little word "patient" from its guidance, causing choppy conditions in US asset markets and the dollar.

 

"Both equity funds produced strong gains, despite weaker equity markets"

 

Five of the seven strategies produced positive returns in March, with the detractors being BlueCrest Capital International and BlueCrest Emerging Markets, although they produced only small losses. Once again, BlueCrest Multi Strategy Credit performed well and both equity funds produced strong gains, despite generally weaker equity markets across the globe.

 

The allocation to BlueCrest Capital International has been progressively reduced for some time and was further reduced by 1.7% for April, bringing the allocation down to 10%, its lowest in AllBlue's history. The fund lost 0.7% in March and conditions remain challenging for the strategy. Good gains were made in North America, particularly in relative value and tactical trading, but were offset by reversals in Europe where curve steepening trades registered losses. These trades are held with some conviction, however, as BlueCrest believe that 30 year rates are substantially disconnected from economic fundamentals. Volatility trading was profitable once again in March as the breaking of the "zero bound" in European interest rates triggered good opportunities.

 

Both BlueCrest Equity Strategies Fund (up by 2.3% on the month) and BlueCrest Quantitative Equity (up by 1.2%) saw positive performance across all regions. Equity Strategies performed particularly strongly across Europe and North America with long/short trading in Europe providing rich opportunities. Quantitative Strategies also saw all the signal sets producing gains. As always, net exposure was tightly bounded around zero and the fund entered April long the consumer discretionary and short the energy sectors. The allocation committee increased exposure to BlueCrest Quantitative Equity by a further 0.5% for April, bringing the allocation to 26%, the largest current holding in AllBlue.

 

BlueTrend's allocation was also increased, by 1.2%, to 11%, with systematic strategies now representing approximately 37% of AllBlue. Mercantile was reduced by 1% to 8%.

 

"An investor call will be held on 23rd April"

 

The shares in the Company have seen consistent buying at around the 5% discount level and so the buyback programme has been relatively quiet during the month.

 

An investor call will be held on 23rd April which will be hosted by Mike Platt, CIO of BlueCrest Capital Management, and Simon Dannatt, member of the AllBlue Allocation Committee. This is open to eligible investors only and details can be found in the Company's announcement of 17th April.

 

Disclaimer:

This document is directed only at: (i) persons having professional experience in matters relating to investments who fall within the definition of "investment professionals" in Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005; or (ii) high net worth bodies corporate, unincorporated associations and partnerships and trustees of high value trusts as described in Article 49(2) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 and persons who receive this document who do not fall within (i) or (ii) above should not rely on or act upon this document.

 

This document is issued by BlueCrest AllBlue Fund Limited (the "Company") to and for the information of its existing shareholders and does not in any jurisdiction constitute investment advice or an invitation to invest in the shares or any other securities of the Company or any other entity (body corporate or otherwise).

 

The Company has used reasonable care to ensure that the information included in this document is accurate at the date of its issue, but does not undertake to update or revise the information, including any information relating to AllBlue Limited and its underlying funds (the "Funds") provided by BlueCrest Capital Management (UK) LLP or any member of the BlueCrest group of companies (as applicable) ("BlueCrest"), or guarantee the accuracy of such information. To the extent permitted by law neither the Company, the Funds, BlueCrest nor their directors or officers shall be liable for any loss or damage that anyone may suffer in reliance on such information.

 

The information in this document may be changed by the Company at any time. Past performance cannot be relied on as a guide to future performance. The Company's investment strategy is speculative and entails substantial risks. The value of an investment may go down as well as up and some or all of the total amount invested may be lost. This document may not, in whole or in part, directly or indirectly, be taken, transmitted or distributed into the United States of America, its territories or possessions or made available to any national, resident or citizen of the United States of America or any other jurisdiction where applicable laws prohibit its release, distribution or publication. Any failure to comply with these restrictions may be a violation of the law in relevant jurisdictions.

 

JTC (Guernsey) Limited

Secretary

 

Tel: Guernsey 01481 702400

 

END OF ANNOUNCEMENT

E&OE - in transmission

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
STREBLFLEZFXBBZ
Date   Source Headline
8th Dec 20219:50 amRNSAquisition of Praxis Fund Services by Sanne Group
3rd Dec 20217:00 amRNSCompany Update
2nd Dec 20213:12 pmRNSNet Asset Value(s)
2nd Dec 20213:12 pmRNS2019 Redemption Portfolio
30th Nov 20214:00 pmRNSTotal Voting Rights
24th Nov 20211:04 pmRNSDirector/PDMR Shareholding
5th Nov 20215:06 pmRNSReturn of Capital to Shareholders
2nd Nov 20214:18 pmRNS2019 Redemption Portfolio
2nd Nov 20214:17 pmRNSNet Asset Value(s)
28th Oct 202112:31 pmRNSResult of AGM
7th Oct 202111:51 amRNSHolding(s) in Company
7th Oct 20217:00 amRNSNotice of AGM
6th Oct 202111:50 amRNSHolding(s) in Company
1st Oct 20211:11 pmRNSNet Asset Value(s)
1st Oct 202112:55 pmRNS2019 Redemption Portfolio
20th Sep 20213:48 pmRNSHalf-year Report
14th Sep 20212:21 pmRNSDirector/PDMR Shareholding
1st Sep 20212:58 pmRNS2019 Redemption Portfolio
1st Sep 20212:55 pmRNSNet Asset Value(s)
31st Aug 20214:40 pmRNSHolding(s) in Company
27th Aug 20217:00 amRNSHolding(s) in Company
19th Aug 20214:00 pmRNSTotal Voting Rights
12th Aug 20214:00 pmRNSReturn of Capital to Shareholders
4th Aug 20215:07 pmRNS2019 Redemption Portfolio
4th Aug 202110:23 amRNSNet Asset Value(s)
27th Jul 20219:15 amRNSDirector Declaration
5th Jul 202112:15 pmRNSApproximate Asset Exposure of the Company
29th Jun 20214:44 pmRNS2019 Redemption Portfolio
29th Jun 20214:38 pmRNSNet Asset Value - Month End Final
21st Jun 20218:31 amRNSDirector/PDMR Shareholding
28th May 20214:30 pmRNSTotal Voting Rights
27th May 20217:00 amRNSHolding(s) in Company
25th May 20214:57 pmRNS2019 Redemption Portfolio
25th May 20214:54 pmRNSNet Asset Value - Month End Final
25th May 20217:00 amRNSDirector/PDMR Shareholding
17th May 202112:54 pmRNSReturn of Capital to shareholders
6th May 20214:48 pmRNSNet Asset Value - Month End Final
6th May 20214:48 pmRNS2019 Redemption Portfolio
22nd Apr 20213:24 pmRNSReturn of Capital to Shareholders
22nd Apr 20217:00 amRNSAnnual Report and Financial Statements
25th Mar 20215:15 pmRNS2019 Redemption Portfolio
25th Mar 20215:14 pmRNSNet Asset Value - Month End Final
5th Mar 20214:51 pmRNS2019 Redemption Portfolio
5th Mar 20214:50 pmRNSNet Asset Value - Month End Final
26th Feb 20214:20 pmRNSTotal Voting Rights
26th Feb 20217:00 amRNSDirector/PDMR Shareholding
19th Feb 20214:38 pmRNSReturn of Capital to Shareholders
19th Feb 20211:10 pmRNSNet Asset Value - Weekly Estimate
18th Feb 20215:12 pmRNSHolding(s) in Company
16th Feb 20211:48 pmRNSNet Asset Value - Weekly Estimate

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.